Stock Market Reviews

ALT (Altimmune, Inc.) News

Get the latest news, insights, and market updates on ALT (Altimmune, Inc.). Explore the news page 4 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)
  Pemvidutide is the only drug currently granted Fast Track Designation in AUD RECLAIM, a Phase 2 trial of pemvidutide in AUD, is currently enrolling GAITHERSBURG, Md., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pemvidutide for the treatment of Alcoho
  Aug 19, 2025 - $ALT
• Altimmune First Half 2025 Earnings: Beats Expectations
  NasdaqGM:ALT 1 Year Share Price vs Fair Value Explore Altimmune's Fair Values from the Community and select yours...
  Aug 14, 2025 - $ALT
• Individual investors account for 51% of Altimmune, Inc.'s (NASDAQ:ALT) ownership, while institutions account for 48%
  NasdaqGM:ALT 1 Year Share Price vs Fair Value Explore Altimmune's Fair Values from the Community and select yours Key...
  Aug 13, 2025 - $ALT
• Altimmune Inc (ALT) Q2 2025 Earnings Call Highlights: Strong Cash Position and Promising Drug ...
  Altimmune Inc (ALT) reports a robust cash reserve and significant progress in drug trials, despite ongoing financial losses and regulatory uncertainties.
  Aug 13, 2025 - $ALT
• Altimmune Announces Second Quarter 2025 Financial Results and Business Update
  Positive data from the IMPACT Phase 2b trial reinforces the potential for pemvidutide to be a highly differentiated MASH therapy Pemvidutide is the first product candidate to achieve statistically significant MASH resolution and weight loss at 24 weeks New data from the IMPACT trial demonstrates potentially class-leading improvements in corrected T1 (cT1), an important marker of liver inflammation and fibrosis End-of-Phase 2 Meeting with FDA expected in Q4 2025 Cash, cash equivalents and short-t
  Aug 12, 2025 - $ALT
• Altimmune Board of Directors Appoints Jerry Durso as Chairman
  Appointment recognizes Mr. Durso’s extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH Mitchel Sayare, Ph.D., to remain on the Board as Independent Director GAITHERSBURG, Md., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that its Board of Directors has appointed Jerry Durso as Chairm
  Aug 11, 2025 - $ALT
• Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025
  GAITHERSBURG, Md., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2025 financial results on Tuesday, August 12, 2025. Altimmune management will host a conference call at 8:30 am E.T. on August 12 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors.
  Aug 5, 2025 - $ALT
• Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect
  ALT readies Q2 report as investors await fresh updates on pemvidutide program in obesity and liver disease studies.
  Jul 25, 2025 - $ALT